{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:36:22Z","timestamp":1784291782643,"version":"3.55.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41585-021-00545-2","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T13:02:48Z","timestamp":1640264568000},"page":"171-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The placebo and nocebo effects in functional urology"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-1771","authenticated-orcid":false,"given":"Hadi","family":"Mostafaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Jilch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta Lisa","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-8558","authenticated-orcid":false,"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-0272","authenticated-orcid":false,"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Schuettfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-6816","authenticated-orcid":false,"given":"Abdulmajeed","family":"Aydh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sari Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus G.","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-6179","authenticated-orcid":false,"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-7097","authenticated-orcid":false,"given":"Sakineh","family":"Hajebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"545_CR1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1037\/0033-2909.130.2.324","volume":"130","author":"S Stewart-Williams","year":"2004","unstructured":"Stewart-Williams, S. & Podd, J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol. Bull. 130, 324 (2004).","journal-title":"Psychol. Bull."},{"key":"545_CR2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/sim.4780020401","volume":"2","author":"CJ McDonald","year":"1983","unstructured":"McDonald, C. J., Mazzuca, S. A. & McCabe, G. P. Jr How much of the placebo \u2018effect\u2019 is really statistical regression? Stat. Med. 2, 417\u2013427 (1983).","journal-title":"Stat. Med."},{"key":"545_CR3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010818-021542","volume":"59","author":"L Colloca","year":"2019","unstructured":"Colloca, L. The placebo effect in pain therapies. Annu. Rev. Pharmacol. Toxicol. 59, 191\u2013211 (2019).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"545_CR4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bmj.318.7185.716","volume":"318","author":"J Aronson","year":"1999","unstructured":"Aronson, J. Please, please me. BMJ 318, 716 (1999).","journal-title":"BMJ"},{"key":"545_CR5","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","volume":"25","author":"F Benedetti","year":"2005","unstructured":"Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S. & Zubieta, J.-K. Neurobiological mechanisms of the placebo effect. J. Neurosci. 25, 10390\u201310402 (2005).","journal-title":"J. Neurosci."},{"key":"545_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.psyneuen.2018.08.008","volume":"105","author":"J Gaab","year":"2019","unstructured":"Gaab, J. The placebo and its effects: a psychoneuroendocrinological perspective. Psychoneuroendocrinology 105, 3\u20138 (2019).","journal-title":"Psychoneuroendocrinology"},{"key":"545_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000490354","volume":"87","author":"AW Evers","year":"2018","unstructured":"Evers, A. W. et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother. Psychosom. 87, 204\u2013210 (2018).","journal-title":"Psychother. Psychosom."},{"key":"545_CR8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bmj.311.7004.551","volume":"311","author":"E Ernst","year":"1995","unstructured":"Ernst, E. & Resch, K. L. Concept of true and perceived placebo effects. BMJ 311, 551\u2013553 (1995).","journal-title":"BMJ"},{"key":"545_CR9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"L Colloca","year":"2020","unstructured":"Colloca, L. & Barsky, A. J. Placebo and nocebo effects. N. Engl. J. Med. 382, 554\u2013561 (2020).","journal-title":"N. Engl. J. Med."},{"key":"545_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2229-3485.106383","volume":"4","author":"U Gupta","year":"2013","unstructured":"Gupta, U. & Verma, M. Placebo in clinical trials. Perspect. Clin. Res. 4, 49 (2013).","journal-title":"Perspect. Clin. Res."},{"key":"545_CR11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF02245754","volume":"102","author":"JJ Lipman","year":"1990","unstructured":"Lipman, J. J. et al. Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response. Psychopharmacology 102, 112\u2013116 (1990).","journal-title":"Psychopharmacology"},{"key":"545_CR12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00001756-200208070-00006","volume":"13","author":"A Pollo","year":"2002","unstructured":"Pollo, A. et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 13, 1383\u20131386 (2002).","journal-title":"Neuroreport"},{"key":"545_CR13","volume":"8","author":"J Howick","year":"2013","unstructured":"Howick, J. et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS ONE 8, e62599 (2013).","journal-title":"PLoS ONE"},{"key":"545_CR14","doi-asserted-by":"crossref","unstructured":"Howick, J. H. The Philosophy of Evidence-Based Medicine (John Wiley & Sons, 2011).","DOI":"10.1002\/9781444342673"},{"key":"545_CR15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrurol.2011.99","volume":"8","author":"A Mangera","year":"2011","unstructured":"Mangera, A., Chapple, C. R., Kopp, Z. S. & Plested, M. The placebo effect in overactive bladder syndrome. Nat. Rev. Urol. 8, 495 (2011).","journal-title":"Nat. Rev. Urol."},{"key":"545_CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/95.1.19","volume":"95","author":"G Chvetzoff","year":"2003","unstructured":"Chvetzoff, G. & Tannock, I. F. Placebo effects in oncology. J. Natl Cancer Inst. 95, 19\u201329 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"545_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJMp1504023","volume":"373","author":"TJ Kaptchuk","year":"2015","unstructured":"Kaptchuk, T. J. & Miller, F. G. Placebo effects in medicine. N. Engl. J. Med. 373, 8\u20139 (2015).","journal-title":"N. Engl. J. Med."},{"key":"545_CR18","volume":"7","author":"FL Bishop","year":"2017","unstructured":"Bishop, F. L. et al. What techniques might be used to harness placebo effects in non-malignant pain? A literature review and survey to develop a taxonomy. BMJ Open 7, e015516 (2017).","journal-title":"BMJ Open"},{"key":"545_CR19","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/jama.1955.02960340022006","volume":"159","author":"HK Beecher","year":"1955","unstructured":"Beecher, H. K. The powerful placebo. J. Am. Med. Assoc. 159, 1602\u20131606 (1955).","journal-title":"J. Am. Med. Assoc."},{"key":"545_CR20","first-page":"459","volume":"109","author":"W H\u00e4user","year":"2012","unstructured":"H\u00e4user, W., Hansen, E. & Enck, P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch. \u00c4rztebl. Int. 109, 459 (2012).","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"545_CR21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","volume":"14","author":"E Kravvariti","year":"2018","unstructured":"Kravvariti, E., Kitas, G. D., Mitsikostas, D. D. & Sfikakis, P. P. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat. Rev. Rheumatol. 14, 727\u2013740 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"545_CR22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuroscience.2015.08.017","volume":"307","author":"B Colagiuri","year":"2015","unstructured":"Colagiuri, B., Schenk, L. A., Kessler, M. D., Dorsey, S. G. & Colloca, L. The placebo effect: from concepts to genes. Neuroscience 307, 171\u2013190 (2015).","journal-title":"Neuroscience"},{"key":"545_CR23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0166-2236(84)80193-9","volume":"7","author":"HL Fields","year":"1984","unstructured":"Fields, H. L. & Levine, J. D. Placebo analgesia \u2014 a role for endorphins? Trends Neurosci. 7, 271\u2013273 (1984).","journal-title":"Trends Neurosci."},{"key":"545_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-018-0263-y","volume":"8","author":"M Peci\u00f1a","year":"2018","unstructured":"Peci\u00f1a, M., Heffernan, J., Wilson, J., Zubieta, J. & Dombrovski, A. Prefrontal expectancy and reinforcement-driven antidepressant placebo effects. Transl. Psychiatry 8, 1\u201311 (2018).","journal-title":"Transl. Psychiatry"},{"key":"545_CR25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.euf.2020.10.010","volume":"7","author":"H Mostafaei","year":"2020","unstructured":"Mostafaei, H. et al. Nocebo response in the pharmacological management of overactive bladder: a systematic review and meta-analysis. Eur. Urol. Focus 7, 1143\u20131153 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"545_CR26","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1098\/rstb.2010.0399","volume":"366","author":"L Colloca","year":"2011","unstructured":"Colloca, L. & Miller, F. G. Harnessing the placebo effect: the need for translational research. Philos. Trans. R. Soc. B Biol. Sci. 366, 1922\u20131930 (2011).","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"545_CR27","first-page":"CD003974","volume":"2010","author":"A Hr\u00f3bjartsson","year":"2010","unstructured":"Hr\u00f3bjartsson, A. & G\u00f8tzsche, P. C. Placebo interventions for all clinical conditions (2010 update). Cochrane Database Syst. Rev. 2010, CD003974 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"545_CR28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2796.2004.01355.x","volume":"256","author":"A Hr\u00f3bjartsson","year":"2004","unstructured":"Hr\u00f3bjartsson, A. & G\u00f8tzsche, P. C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J. Intern. Med. 256, 91\u2013100 (2004).","journal-title":"J. Intern. Med."},{"key":"545_CR29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","volume":"34","author":"AG Barnett","year":"2005","unstructured":"Barnett, A. G., Van Der Pols, J. C. & Dobson, A. J. Regression to the mean: what it is and how to deal with it. Int. J. Epidemiol. 34, 215\u2013220 (2005).","journal-title":"Int. J. Epidemiol."},{"key":"545_CR30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0895-4356(97)00203-5","volume":"50","author":"GS Kienle","year":"1997","unstructured":"Kienle, G. S. & Kiene, H. The powerful placebo effect: fact or fiction? J. Clin. Epidemiol. 50, 1311\u20131318 (1997).","journal-title":"J. Clin. Epidemiol."},{"key":"545_CR31","first-page":"CD003974","volume":"2004","author":"A Hr\u00f3bjartsson","year":"2004","unstructured":"Hr\u00f3bjartsson, A. & G\u00f8tzsche, P. C. Placebo interventions for all clinical conditions. Cochrane Database Syst. Rev. 2004, CD003974 (2004).","journal-title":"Cochrane Database Syst. Rev."},{"key":"545_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","volume":"147","author":"F Benedetti","year":"2007","unstructured":"Benedetti, F., Lanotte, M., Lopiano, L. & Colloca, L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 147, 260\u2013271 (2007).","journal-title":"Neuroscience"},{"key":"545_CR33","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1523\/JNEUROSCI.2944-08.2008","volume":"28","author":"J Kong","year":"2008","unstructured":"Kong, J. et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J. Neurosci. 28, 13354\u201313362 (2008).","journal-title":"J. Neurosci."},{"key":"545_CR34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1755738019842596","volume":"12","author":"T Nolan","year":"2019","unstructured":"Nolan, T. The placebo effect in general practice. InnovAiT 12, 404\u2013407 (2019).","journal-title":"InnovAiT"},{"key":"545_CR35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/15265161.2011.652798","volume":"12","author":"RE Wells","year":"2012","unstructured":"Wells, R. E. & Kaptchuk, T. J. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am. J. Bioeth. 12, 22\u201329 (2012).","journal-title":"Am. J. Bioeth."},{"key":"545_CR36","doi-asserted-by":"crossref","first-page":"i2250","DOI":"10.1136\/bmj.i2250","volume":"353","author":"P Tyrer","year":"2016","unstructured":"Tyrer, P., Eilenberg, T., Fink, P., Hedman, E. & Tyrer, H. Health anxiety: the silent, disabling epidemic. BMJ 353, i2250 (2016).","journal-title":"BMJ"},{"key":"545_CR37","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s, S., Villier, C. & Mallaret, M. The nocebo effect of drugs. Pharm. Res. Perspect. 4, e00208 (2016).","journal-title":"Pharm. Res. Perspect."},{"key":"545_CR38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1467-8519.2012.01983.x","volume":"28","author":"S Cohen","year":"2014","unstructured":"Cohen, S. The nocebo effect of informed consent. Bioethics 28, 147\u2013154 (2014).","journal-title":"Bioethics"},{"key":"545_CR39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.294.2.183","volume":"294","author":"JK Ockene","year":"2005","unstructured":"Ockene, J. K. et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 294, 183\u2013193 (2005).","journal-title":"JAMA"},{"key":"545_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3959(03)00073-3","volume":"105","author":"L Vase","year":"2003","unstructured":"Vase, L., Robinson, M. E., Verne, G. N. & Price, D. D. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients: an empirical investigation. Pain 105, 17\u201325 (2003).","journal-title":"Pain"},{"key":"545_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3959(99)00081-0","volume":"83","author":"DD Price","year":"1999","unstructured":"Price, D. D. et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83, 147\u2013156 (1999).","journal-title":"Pain"},{"key":"545_CR42","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1523\/JNEUROSCI.19-09-03639.1999","volume":"19","author":"F Benedetti","year":"1999","unstructured":"Benedetti, F., Arduino, C. & Amanzio, M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J. Neurosci. 19, 3639\u20133648 (1999).","journal-title":"J. Neurosci."},{"key":"545_CR43","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1096\/fj.02-0389com","volume":"16","author":"MU Goebel","year":"2002","unstructured":"Goebel, M. U. et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J. 16, 1869\u20131873 (2002).","journal-title":"FASEB J."},{"key":"545_CR44","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1523\/JNEUROSCI.23-10-04315.2003","volume":"23","author":"F Benedetti","year":"2003","unstructured":"Benedetti, F. et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo\/nocebo responses. J. Neurosci. 23, 4315\u20134323 (2003).","journal-title":"J. Neurosci."},{"key":"545_CR45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1146\/annurev-psych-010418-102907","volume":"70","author":"KJ Petrie","year":"2019","unstructured":"Petrie, K. J. & Rief, W. Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects. Annu. Rev. Psychol. 70, 599\u2013625 (2019).","journal-title":"Annu. Rev. Psychol."},{"key":"545_CR46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fpsyt.2019.00449","volume":"10","author":"P B\u0105bel","year":"2019","unstructured":"B\u0105bel, P. Classical conditioning as a distinct mechanism of placebo effects. Front. Psychiatry 10, 449 (2019).","journal-title":"Front. Psychiatry"},{"key":"545_CR47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/pr.114.009423","volume":"67","author":"M Schedlowski","year":"2015","unstructured":"Schedlowski, M., Enck, P., Rief, W. & Bingel, U. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol. Rev. 67, 697\u2013730 (2015).","journal-title":"Pharmacol. Rev."},{"key":"545_CR48","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jama.2012.115","volume":"307","author":"L Colloca","year":"2012","unstructured":"Colloca, L. & Finniss, D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 307, 567\u2013568 (2012).","journal-title":"JAMA"},{"key":"545_CR49","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/acr.20160","volume":"62","author":"Y Nestoriuc","year":"2010","unstructured":"Nestoriuc, Y., Orav, E. J., Liang, M. H., Horne, R. & Barsky, A. J. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res. 62, 791\u2013799 (2010).","journal-title":"Arthritis Care Res."},{"key":"545_CR50","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1352458510370793","volume":"16","author":"D Papadopoulos","year":"2010","unstructured":"Papadopoulos, D. & Mitsikostas, D. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult. Scler. J. 16, 816\u2013828 (2010).","journal-title":"Mult. Scler. J."},{"key":"545_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3906-2","volume":"21","author":"J He","year":"2020","unstructured":"He, J., Morales, D. R. & Guthrie, B. Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review. Trials 21, 1\u201311 (2020).","journal-title":"Trials"},{"key":"545_CR52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jclinepi.2017.03.001","volume":"87","author":"JS Jensen","year":"2017","unstructured":"Jensen, J. S., Bielefeldt, A. \u00d8. & Hr\u00f3bjartsson, A. Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview. J. Clin. Epidemiol. 87, 35\u201346 (2017).","journal-title":"J. Clin. Epidemiol."},{"key":"545_CR53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ebiom.2017.09.031","volume":"24","author":"V Faria","year":"2017","unstructured":"Faria, V. et al. Do you believe it? Verbal suggestions influence the clinical and neural effects of escitalopram in social anxiety disorder: a randomized trial. EBioMedicine 24, 179\u2013188 (2017).","journal-title":"EBioMedicine"},{"key":"545_CR54","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1474-4422(04)00908-1","volume":"3","author":"L Colloca","year":"2013","unstructured":"Colloca, L., Lopiano, L., Lanotte, M. & Benedetti, F. Overt versus covert treatment for pain, anxiety, and Parkinson\u2019s disease. Lancet Neurol. 3, 679\u2013684 (2013).","journal-title":"Lancet Neurol."},{"key":"545_CR55","first-page":"427","volume":"5","author":"L Santana","year":"2011","unstructured":"Santana, L. & Fontenelle, L. F. A review of studies concerning treatment adherence of patients with anxiety disorders. Patient Prefer. Adherence 5, 427\u2013439 (2011).","journal-title":"Patient Prefer. Adherence"},{"key":"545_CR56","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s001920050039","volume":"10","author":"C Chaliha","year":"1999","unstructured":"Chaliha, C. & Stanton, S. The ethnic cultural and social aspects of incontinence \u2014 a pilot study. Int. Urogynecol. J. 10, 166\u2013170 (1999).","journal-title":"Int. Urogynecol. J."},{"key":"545_CR57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.amjmed.2014.08.031","volume":"128","author":"M Greville-Harris","year":"2015","unstructured":"Greville-Harris, M. & Dieppe, P. Bad is more powerful than good: the nocebo response in medical consultations. Am. J. Med. 128, 126\u2013129 (2015).","journal-title":"Am. J. Med."},{"key":"545_CR58","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.eururo.2006.05.014","volume":"50","author":"JHS van Leeuwen","year":"2006","unstructured":"van Leeuwen, J. H. S., Castro, R., Busse, M. & Bemelmans, B. L. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur. Urol. 50, 440\u2013453 (2006).","journal-title":"Eur. Urol."},{"key":"545_CR59","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","volume":"12","author":"P Enck","year":"2013","unstructured":"Enck, P., Bingel, U., Schedlowski, M. & Rief, W. The placebo response in medicine: minimize, maximize or personalize? Nat. Rev. Drug Discov. 12, 191 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"545_CR60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pain.2008.02.006","volume":"136","author":"L Colloca","year":"2008","unstructured":"Colloca, L., Sigaudo, M. & Benedetti, F. The role of learning in nocebo and placebo effects. Pain 136, 211\u2013218 (2008).","journal-title":"Pain"},{"key":"545_CR61","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","volume":"4","author":"N Mondaini","year":"2007","unstructured":"Mondaini, N. et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J. Sex. Med. 4, 1708\u20131712 (2007).","journal-title":"J. Sex. Med."},{"key":"545_CR62","doi-asserted-by":"crossref","unstructured":"Many sexual adverse effects of finasteride are attributable to a nocebo effect. Nat. Clin. Pract. Urol. 5, 66\u201366 (2008).","DOI":"10.1038\/ncpuro1012"},{"key":"545_CR63","unstructured":"Walsh, J. J. Old-Time Makers of Medicine: The Story of The Students And Teachers of the Sciences Related to Medicine During the Middle Ages (Good Press, 2019)."},{"key":"545_CR64","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1176\/ajp.113.12.1103","volume":"113","author":"LH Gliedman","year":"1957","unstructured":"Gliedman, L. H., Gantt, W. H. & Teitelbaum, H. A. Some implications of conditional reflex studies for placebo research. Am. J. Psychiatry 113, 1103\u20131107 (1957).","journal-title":"Am. J. Psychiatry"},{"key":"545_CR65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/bs.3830020203","volume":"2","author":"AA Kurland","year":"1957","unstructured":"Kurland, A. A. The drug placebo \u2014 its psychodynamic and conditional reflex action. Behav. Sci. 2, 101\u2013110 (1957).","journal-title":"Behav. Sci."},{"key":"545_CR66","unstructured":"Pavlov, I. P. & Anrep, G. V. Conditioned Reflexes: an Investigation of the Physiological Activity of the Cerebral Cortex (Oxford University Press, 1927)."},{"key":"545_CR67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5694\/j.1326-5377.1969.tb49784.x","volume":"1","author":"W Lang","year":"1969","unstructured":"Lang, W. & Rand, M. A placebo response as a conditional reflex to glyceryl trinitrate. Med. J. Aust. 1, 12\u201314 (1969).","journal-title":"Med. J. Aust."},{"key":"545_CR68","doi-asserted-by":"crossref","unstructured":"Kirsch, I. & Heap, M. Hypnosis: Theory, Research and Application (Routledge, 2017).","DOI":"10.4324\/9781315252858"},{"key":"545_CR69","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1037\/0003-066X.40.11.1189","volume":"40","author":"I Kirsch","year":"1985","unstructured":"Kirsch, I. Response expectancy as a determinant of experience and behavior. Am. Psychol. 40, 1189 (1985).","journal-title":"Am. Psychol."},{"key":"545_CR70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1037\/0735-7044.102.2.319","volume":"102","author":"I Kirsch","year":"1988","unstructured":"Kirsch, I. & Weixel, L. J. Double-blind versus deceptive administration of a placebo. Behav. Neurosci. 102, 319 (1988).","journal-title":"Behav. Neurosci."},{"key":"545_CR71","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/pm\/pnx177","volume":"19","author":"P B\u0105bel","year":"2018","unstructured":"B\u0105bel, P. et al. How classical conditioning shapes placebo analgesia: hidden versus open conditioning. Pain. Med. 19, 1156\u20131169 (2018).","journal-title":"Pain. Med."},{"key":"545_CR72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181856","volume":"12","author":"P B\u0105bel","year":"2017","unstructured":"B\u0105bel, P. et al. Classical conditioning without verbal suggestions elicits placebo analgesia and nocebo hyperalgesia. PLoS ONE 12, e0181856 (2017).","journal-title":"PLoS ONE"},{"key":"545_CR73","first-page":"E157","volume":"14","author":"L Manchikanti","year":"2011","unstructured":"Manchikanti, L., Giordano, J., Fellows, B. & Hirsch, J. A. Placebo and nocebo in interventional pain management: a friend or a foe-or simply foes. Pain. Phys. 14, E157\u2013E175 (2011).","journal-title":"Pain. Phys."},{"key":"545_CR74","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1126\/science.1093065","volume":"303","author":"TD Wager","year":"2004","unstructured":"Wager, T. D. et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303, 1162\u20131167 (2004).","journal-title":"Science"},{"key":"545_CR75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/hbm.21471","volume":"34","author":"M Amanzio","year":"2013","unstructured":"Amanzio, M., Benedetti, F., Porro, C. A., Palermo, S. & Cauda, F. Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. Hum. Brain Mapp. 34, 738\u2013752 (2013).","journal-title":"Hum. Brain Mapp."},{"key":"545_CR76","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.neuron.2014.10.023","volume":"84","author":"F Benedetti","year":"2014","unstructured":"Benedetti, F. Placebo effects: from the neurobiological paradigm to translational implications. Neuron 84, 623\u2013637 (2014).","journal-title":"Neuron"},{"key":"545_CR77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0090-4295(01)01633-8","volume":"59","author":"BF Blok","year":"2002","unstructured":"Blok, B. F. Central pathways controlling micturition and urinary continence. Urology 59, 13\u201317 (2002).","journal-title":"Urology"},{"key":"545_CR78","doi-asserted-by":"crossref","unstructured":"Benedetti, F. Placebo Effects (Oxford University Press, USA, 2014).","DOI":"10.1093\/acprof:oso\/9780198705086.001.0001"},{"key":"545_CR79","unstructured":"Colloca, L., Flaten, M. A. & Meissner, K. Placebo and Pain: from Bench to Bedside (Academic Press, 2013)."},{"key":"545_CR80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/nau.20789","volume":"29","author":"G Holstege","year":"2010","unstructured":"Holstege, G. The emotional motor system and micturition control. Neurourol. Urodyn. 29, 42\u201348 (2010).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0304-3940(94)90848-6","volume":"166","author":"BF Blok","year":"1994","unstructured":"Blok, B. F. & Holstege, G. Direct projections from the periaqueductal gray to the pontine micturition center (M-region). An anterograde and retrograde tracing study in the cat. Neurosci. Lett. 166, 93\u201396 (1994).","journal-title":"Neurosci. Lett."},{"key":"545_CR82","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00210-007-0209-z","volume":"377","author":"N Yoshimura","year":"2008","unstructured":"Yoshimura, N. et al. Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch. Pharmacol. 377, 437\u2013448 (2008).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"545_CR83","unstructured":"Andersson, K.-E. & Gratzke, C. in Textbook of the Neurogenic Bladder 95\u2013114 (CRC Press, 2008)."},{"key":"545_CR84","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1060937","volume":"293","author":"R De la Fuente-Fern\u00e1ndez","year":"2001","unstructured":"De la Fuente-Fern\u00e1ndez, R. et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease. Science 293, 1164\u20131166 (2001).","journal-title":"Science"},{"key":"545_CR85","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2003.11.019","volume":"56","author":"R de la Fuente-Fern\u00e1ndez","year":"2004","unstructured":"de la Fuente-Fern\u00e1ndez, R., Schulzer, M. & Stoessl, A. J. Placebo mechanisms and reward circuitry: clues from Parkinson\u2019s disease. Biol. Psychiatry 56, 67\u201371 (2004).","journal-title":"Biol. Psychiatry"},{"key":"545_CR86","first-page":"57","volume":"111","author":"F Van der Aa","year":"2004","unstructured":"Van der Aa, F., Ost, D. & De Ridder, D. J. M. K. Interstitial cells of the bladder: the missing link? BJOG 111, 57\u201360 (2004).","journal-title":"BJOG"},{"key":"545_CR87","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1523\/JNEUROSCI.19-01-00484.1999","volume":"19","author":"M Amanzio","year":"1999","unstructured":"Amanzio, M. & Benedetti, F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci. 19, 484\u2013494 (1999).","journal-title":"J. Neurosci."},{"key":"545_CR88","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0140-6736(78)92762-9","volume":"312","author":"J Levine","year":"1978","unstructured":"Levine, J., Gordon, N. & Fields, H. The mechanism of placebo analgesia. Lancet 312, 654\u2013657 (1978).","journal-title":"Lancet"},{"key":"545_CR89","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0304-3959(95)00179-4","volume":"64","author":"F Benedetti","year":"1996","unstructured":"Benedetti, F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64, 535\u2013543 (1996).","journal-title":"Pain"},{"key":"545_CR90","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/j.1476-5381.1996.tb15643.x","volume":"118","author":"RG Pertwee","year":"1996","unstructured":"Pertwee, R. G. & Fernando, S. R. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118, 2053\u20132058 (1996).","journal-title":"Br. J. Pharmacol."},{"key":"545_CR91","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","volume":"17","author":"R Freeman","year":"2006","unstructured":"Freeman, R. et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. 17, 636\u2013641 (2006).","journal-title":"Int. Urogynecol. J."},{"key":"545_CR92","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.bja.2019.01.040","volume":"123","author":"L Vase","year":"2019","unstructured":"Vase, L. & Wartolowska, K. Pain, placebo, and test of treatment efficacy: a narrative review. Br. J. Anaesth. 123, e254\u2013e262 (2019).","journal-title":"Br. J. Anaesth."},{"key":"545_CR93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.pupt.2013.01.006","volume":"26","author":"F Benedetti","year":"2013","unstructured":"Benedetti, F. & Amanzio, M. Mechanisms of the placebo response. Pulm. Pharmacol. Ther. 26, 520\u2013523 (2013).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"545_CR94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3959(97)03346-0","volume":"71","author":"F Benedetti","year":"1997","unstructured":"Benedetti, F., Amanzio, M., Casadio, C., Oliaro, A. & Maggi, G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 71, 135\u2013140 (1997).","journal-title":"Pain"},{"key":"545_CR95","first-page":"246","volume":"15","author":"F Galton","year":"1886","unstructured":"Galton, F. Regression towards mediocrity in hereditary stature. J. Anthropol. Inst. Gt. Br. Irel. 15, 246\u2013263 (1886).","journal-title":"J. Anthropol. Inst. Gt. Br. Irel."},{"key":"545_CR96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0090-4295(97)00609-2","volume":"51","author":"SM Sech","year":"1998","unstructured":"Sech, S. M. et al. The so-called \u201cplacebo effect\u201d in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 51, 242\u2013250 (1998).","journal-title":"Urology"},{"key":"545_CR97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euf.2019.06.010","volume":"5","author":"C Chapple","year":"2019","unstructured":"Chapple, C. What is new in functional urology? Eur. Urol. Focus. 5, 307\u2013309 (2019).","journal-title":"Eur. Urol. Focus."},{"key":"545_CR98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen, B. T. et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol. Urodynam. 29, 4\u201320 (2010).","journal-title":"Neurourol. Urodynam."},{"key":"545_CR99","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","volume":"77","author":"KS Coyne","year":"2011","unstructured":"Coyne, K. S. et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77, 1081\u20131087 (2011).","journal-title":"Urology"},{"key":"545_CR100","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1464-410X.2008.07573.x","volume":"101","author":"DE Irwin","year":"2008","unstructured":"Irwin, D. E. et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 101, 1381\u20131387 (2008).","journal-title":"BJU Int."},{"key":"545_CR101","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"W Stewart","year":"2003","unstructured":"Stewart, W. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20, 327\u2013336 (2003).","journal-title":"World J. Urol."},{"key":"545_CR102","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom, I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760\u2013766 (2001).","journal-title":"BJU Int."},{"key":"545_CR103","first-page":"71","volume":"8","author":"RS Eapen","year":"2016","unstructured":"Eapen, R. S. & Radomski, S. B. Review of the epidemiology of overactive bladder. Res. Rep. Urol. 8, 71 (2016).","journal-title":"Res. Rep. Urol."},{"key":"545_CR104","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","volume":"50","author":"K-E Andersson","year":"1997","unstructured":"Andersson, K.-E. The overactive bladder: pharmacologic basis of drug treatment. Urology 50, 74\u201384 (1997).","journal-title":"Urology"},{"key":"545_CR105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","volume":"22","author":"D Robinson","year":"2019","unstructured":"Robinson, D. & Cardozo, L. Managing overactive bladder. Climacteric 22, 250\u2013256 (2019).","journal-title":"Climacteric"},{"key":"545_CR106","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","volume":"100","author":"O Yamaguchi","year":"2007","unstructured":"Yamaguchi, O. et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 100, 579\u2013587 (2007).","journal-title":"BJU Int."},{"key":"545_CR107","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/nau.23852","volume":"38","author":"DG Shin","year":"2019","unstructured":"Shin, D. G. et al. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Neurourol. Urodyn. 38, 295\u2013304 (2019).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR108","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz, F. et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur. Urol. 60, 742\u2013750 (2011).","journal-title":"Eur. Urol."},{"key":"545_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.02.005","author":"H Mostafaei","year":"2021","unstructured":"Mostafaei, H. et al. Placebo response in patients with oral therapy for overactive bladder: a systematic review and meta-analysis. Eur. Urol. Focus https:\/\/doi.org\/10.1016\/j.euf.2021.02.005 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"545_CR110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.juro.2013.02.037","volume":"190","author":"PK Sand","year":"2013","unstructured":"Sand, P. K., Dmochowski, R. R., Reddy, J. & van der Meulen, E. A. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J. Urol. 190, 958\u2013964 (2013).","journal-title":"J. Urol."},{"key":"545_CR111","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ju.0000069827.09120.79","volume":"170","author":"TM Johnson","year":"2003","unstructured":"Johnson, T. M. et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J. Urol. 170, 145\u2013148 (2003).","journal-title":"J. Urol."},{"key":"545_CR112","first-page":"10699","volume":"28","author":"JG Blaivas","year":"2021","unstructured":"Blaivas, J. G. et al. Overactive bladder phenotypes: development and preliminary data. Can. J. Urol. 28, 10699\u201310704 (2021).","journal-title":"Can. J. Urol."},{"key":"545_CR113","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2017.04.016","volume":"106","author":"S Herschorn","year":"2017","unstructured":"Herschorn, S., Chapple, C. R., Snijder, R., Siddiqui, E. & Cardozo, L. Could reduced fluid intake cause the placebo effect seen in overactive bladder clinical trials? Analysis of a large solifenacin integrated database. Urology 106, 55\u201359 (2017).","journal-title":"Urology"},{"key":"545_CR114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejogrb.2020.01.023","volume":"246","author":"G Baines","year":"2020","unstructured":"Baines, G., Araklitis, G., Flint, R., Robinson, D. & Cardozo, L. What affects the placebo effect? Eur. J. Obstet. Gynecol. Reprod. Biol. 246, 134\u2013137 (2020).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"545_CR115","doi-asserted-by":"crossref","unstructured":"Avery, J. C., Braunack-Mayer, A. J., Stocks, N. P., Taylor, A. & Duggan, P. Psychological Perspectives in Urinary Incontinence: a Metasynthesis (OA Women\u2019s Health, 2013).","DOI":"10.13172\/2053-0501-1-1-662"},{"key":"545_CR116","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin, D. E., Kopp, Z. S., Agatep, B., Milsom, I. & Abrams, P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 108, 1132\u20131138 (2011).","journal-title":"BJU Int."},{"key":"545_CR117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13697137.2018.1543263","volume":"22","author":"I Milsom","year":"2019","unstructured":"Milsom, I. & Gyhagen, M. The prevalence of urinary incontinence. Climacteric 22, 217\u2013222 (2019).","journal-title":"Climacteric"},{"key":"545_CR118","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/nau.24342","volume":"39","author":"H Mostafaei","year":"2020","unstructured":"Mostafaei, H. et al. Prevalence of female urinary incontinence in the developing world: a systematic review and meta-analysis \u2014 a report from the Developing World Committee of the International Continence Society and Iranian Research Center for Evidence Based Medicine. Neurourol. Urodyn. 39, 1063\u20131086 (2020).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR119","first-page":"398","volume":"98","author":"L Wilson","year":"2001","unstructured":"Wilson, L., Brown, J. S., Shin, G. P., Luc, K.-O. & Subak, L. L. Annual direct cost of urinary incontinence. Obstet. Gynecol. 98, 398\u2013406 (2001).","journal-title":"Obstet. Gynecol."},{"key":"545_CR120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2009.06.096","volume":"75","author":"ML Ganz","year":"2010","unstructured":"Ganz, M. L. et al. Economic costs of overactive bladder in the United States. Urology 75, 526\u2013532 (2010).","journal-title":"Urology"},{"key":"545_CR121","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.23897","volume":"38","author":"C D\u2019Ancona","year":"2019","unstructured":"D\u2019Ancona, C. et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol. Urodyn. 38, 433\u2013477 (2019).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR122","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/nau.23551","volume":"37","author":"P Abrams","year":"2018","unstructured":"Abrams, P. et al. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol. Urodyn. 37, 2271\u20132272 (2018).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR123","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2004.03.089","volume":"191","author":"I Yalcin","year":"2004","unstructured":"Yalcin, I. & Bump, R. C. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Am. J. Obstet. Gynecol. 191, 194\u2013197 (2004).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"545_CR124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00192-013-2269-6","volume":"25","author":"N Klarskov","year":"2014","unstructured":"Klarskov, N., Darekar, A., Scholfield, D., Whelan, L. & Lose, G. Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry. Int. Urogynecol. J. 25, 755\u2013760 (2014).","journal-title":"Int. Urogynecol. J."},{"key":"545_CR125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejogrb.2018.03.038","volume":"224","author":"M Blaganje","year":"2018","unstructured":"Blaganje, M. et al. Non-ablative Er: YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 224, 153\u2013158 (2018).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"545_CR126","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11255-013-0410-6","volume":"45","author":"J Li","year":"2013","unstructured":"Li, J. et al. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int. Urol. Nephrol. 45, 679\u2013686 (2013).","journal-title":"Int. Urol. Nephrol."},{"key":"545_CR127","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jsxm.2016.09.020","volume":"13","author":"SJ Parish","year":"2016","unstructured":"Parish, S. J. et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions \u2014 part II. J. Sex. Med. 13, 1888\u20131906 (2016).","journal-title":"J. Sex. Med."},{"key":"545_CR128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","volume":"281","author":"EO Laumann","year":"1999","unstructured":"Laumann, E. O., Paik, A. & Rosen, R. C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281, 537\u2013544 (1999).","journal-title":"JAMA"},{"key":"545_CR129","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-5347(05)67828-7","volume":"163","author":"R Basson","year":"2000","unstructured":"Basson, R. et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol. 163, 888\u2013893 (2000).","journal-title":"J. Urol."},{"key":"545_CR130","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1743-6109.2007.00578.x","volume":"4","author":"A Bradford","year":"2007","unstructured":"Bradford, A. & Meston, C. Correlates of placebo response in the treatment of sexual dysfunction in women: a preliminary report. J. Sex. Med. 4, 1345\u20131351 (2007).","journal-title":"J. Sex. Med."},{"key":"545_CR131","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1067\/mob.2003.117","volume":"188","author":"K Modelska","year":"2003","unstructured":"Modelska, K. & Cummings, S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am. J. Obstet. Gynecol. 188, 286\u2013293 (2003).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"545_CR132","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/AOG.0000000000002733","volume":"132","author":"JM Weinberger","year":"2018","unstructured":"Weinberger, J. M. et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet. Gynecol. 132, 453\u2013458 (2018).","journal-title":"Obstet. Gynecol."},{"key":"545_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00926230590475206","volume":"31","author":"M Wiegel","year":"2005","unstructured":"Wiegel, M., Meston, C. & Rosen, R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J. Sex. Marital. Ther. 31, 1\u201320 (2005).","journal-title":"J. Sex. Marital. Ther."},{"key":"545_CR134","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1743-6109.2010.02007.x","volume":"8","author":"A Bradford","year":"2011","unstructured":"Bradford, A. & Meston, C. M. Behavior and symptom change among women treated with placebo for sexual dysfunction. J. Sex. Med. 8, 191\u2013201 (2011).","journal-title":"J. Sex. Med."},{"key":"545_CR135","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1743-6109.2012.02941.x","volume":"10","author":"A Bradford","year":"2013","unstructured":"Bradford, A. Listening to placebo in clinical trials for female sexual dysfunction. J. Sex. Med. 10, 451\u2013459 (2013).","journal-title":"J. Sex. Med."},{"key":"545_CR136","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1743-6109.2007.00668.x","volume":"5","author":"LR DeRogatis","year":"2008","unstructured":"DeRogatis, L. R. & Burnett, A. L. The epidemiology of sexual dysfunctions. J. Sex. Med. 5, 289\u2013300 (2008).","journal-title":"J. Sex. Med."},{"key":"545_CR137","first-page":"265","volume":"14","author":"S Gur","year":"2013","unstructured":"Gur, S. et al. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. Curr. Drug Metab. 14, 265\u2013269 (2013).","journal-title":"Curr. Drug Metab."},{"key":"545_CR138","first-page":"212248","volume":"2013","author":"D Swearingen","year":"2013","unstructured":"Swearingen, D., Nehra, A., Morelos, S. & Peterson, C. A. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context 2013, 212248 (2013).","journal-title":"Drugs Context"},{"key":"545_CR139","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1111\/j.1743-6109.2009.01496.x","volume":"6","author":"AC De Araujo","year":"2009","unstructured":"De Araujo, A. C. et al. The management of erectile dysfunction with placebo only: does it work? J. Sex. Med. 6, 3440\u20133448 (2009).","journal-title":"J. Sex. Med."},{"key":"545_CR140","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1176\/appi.ajp.158.10.1623","volume":"158","author":"SN Seidman","year":"2001","unstructured":"Seidman, S. N., Roose, S. P., Menza, M. A., Shabsigh, R. & Rosen, R. C. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am. J. Psychiatry 158, 1623\u20131630 (2001).","journal-title":"Am. J. Psychiatry"},{"key":"545_CR141","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jsxm.2018.03.089","volume":"15","author":"JP Mulhall","year":"2018","unstructured":"Mulhall, J. P., Carlsson, M., Stecher, V. & Tseng, L.-J. Predictors of erectile function normalization in men with erectile dysfunction treated with placebo. J. Sex. Med. 15, 866\u2013872 (2018).","journal-title":"J. Sex. Med."},{"key":"545_CR142","doi-asserted-by":"crossref","first-page":"e201423","DOI":"10.1001\/jamanetworkopen.2020.1423","volume":"3","author":"A Stridh","year":"2020","unstructured":"Stridh, A. et al. Placebo responses among men with erectile dysfunction enrolled in phosphodiesterase 5 inhibitor trials: a systematic review and meta-analysis. JAMA Netw. Open 3, e201423\u2013e201423 (2020).","journal-title":"JAMA Netw. Open"},{"key":"545_CR143","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00926230590513465","volume":"31","author":"T Melnik","year":"2005","unstructured":"Melnik, T. & Abdo, C. H. Psychogenic erectile dysfunction: comparative study of three therapeutic approaches. J. Sex. Marital. Ther. 31, 243\u2013255 (2005).","journal-title":"J. Sex. Marital. Ther."},{"key":"545_CR144","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1037\/hea0000282","volume":"35","author":"K Faasse","year":"2016","unstructured":"Faasse, K., Martin, L. R., Grey, A., Gamble, G. & Petrie, K. J. Impact of brand or generic labeling on medication effectiveness and side effects. Health Psychol. 35, 187 (2016).","journal-title":"Health Psychol."},{"key":"545_CR145","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.juro.2011.10.040","volume":"187","author":"KS Konkle","year":"2012","unstructured":"Konkle, K. S. et al. Comparison of an interstitial cystitis\/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J. Urol. 187, 508\u2013512 (2012).","journal-title":"J. Urol."},{"key":"545_CR146","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0090-4295(99)80337-9","volume":"49","author":"DA Nigro","year":"1997","unstructured":"Nigro, D. A. et al. Associations among cystoscopic and urodynamic findings for women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology 49, 86\u201392 (1997).","journal-title":"Urology"},{"key":"545_CR147","first-page":"112","volume":"4","author":"JC Nickel","year":"2002","unstructured":"Nickel, J. C. Interstitial cystitis: characterization and management of an enigmatic urologic syndrome. Rev. Urol. 4, 112 (2002).","journal-title":"Rev. Urol."},{"key":"545_CR148","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.juro.2018.02.011","volume":"200","author":"JC Nickel","year":"2018","unstructured":"Nickel, J. C. & Moldwin, R. FDA BRUDAC 2018 Criteria for Interstitial Cystitis\/Bladder Pain Syndrome Clinical Trials: future direction for research. J. Urol. 200, 39\u201342 (2018).","journal-title":"J. Urol."},{"key":"545_CR149","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1056\/NEJM191505061721802","volume":"172","author":"GL Hunner","year":"1915","unstructured":"Hunner, G. L. A rare type of bladder ulcer in women; report of cases. Boston Med. Surgical J. 172, 660\u2013664 (1915).","journal-title":"Boston Med. Surgical J."},{"key":"545_CR150","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s00192-005-1301-x","volume":"16","author":"P Hanno","year":"2005","unstructured":"Hanno, P. International Consultation on IC-Rome, September 2004\/Forging an International Consensus: progress in painful bladder syndrome\/interstitial cystitis. Int. Urogynecol. J. 16, S2 (2005).","journal-title":"Int. Urogynecol. J."},{"key":"545_CR151","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/nau.23072","volume":"36","author":"R Doggweiler","year":"2017","unstructured":"Doggweiler, R. et al. A standard for terminology in chronic pelvic pain syndromes: a report from the chronic pelvic pain working group of the International Continence Society. Neurourol. Urodyn. 36, 984\u20131008 (2017).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR152","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2011.03.132","volume":"186","author":"SH Berry","year":"2011","unstructured":"Berry, S. H. et al. Prevalence of symptoms of bladder pain syndrome\/interstitial cystitis among adult females in the United States. J. Urol. 186, 540\u2013544 (2011).","journal-title":"J. Urol."},{"key":"545_CR153","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1067\/mob.2002.127375","volume":"187","author":"CL Parsons","year":"2002","unstructured":"Parsons, C. L. et al. The prevalence of interstitial cystitis in gynecologic patients with pelvic pain, as detected by intravesical potassium sensitivity. Am. J. Obstet. Gynecol. 187, 1395\u20131400 (2002).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"545_CR154","first-page":"S9","volume":"4","author":"GR Sant","year":"2002","unstructured":"Sant, G. R. Etiology, pathogenesis, and diagnosis of interstitial cystitis. Rev. Urol. 4, S9 (2002).","journal-title":"Rev. Urol."},{"key":"545_CR155","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.juro.2009.12.106","volume":"183","author":"HE Foster","year":"2010","unstructured":"Foster, H. E. et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis\/painful bladder syndrome. J. Urol. 183, 1853\u20131858 (2010).","journal-title":"J. Urol."},{"key":"545_CR156","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/03007995.2019.1586401","volume":"35","author":"A van Ophoven","year":"2019","unstructured":"van Ophoven, A., Vonde, K., Koch, W., Auerbach, G. & Maag, K. P. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis\/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr. Med. Res. Opin. 35, 1495\u20131503 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"545_CR157","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2014.09.036","volume":"193","author":"JC Nickel","year":"2015","unstructured":"Nickel, J. C. et al. Pentosan polysulfate sodium for treatment of interstitial cystitis\/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J. Urol. 193, 857\u2013862 (2015).","journal-title":"J. Urol."},{"key":"545_CR158","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urology.2014.04.011","volume":"84","author":"PC Bosch","year":"2014","unstructured":"Bosch, P. C. Examination of the significant placebo effect in the treatment of interstitial cystitis\/bladder pain syndrome. Urology 84, 321\u2013326 (2014).","journal-title":"Urology"},{"key":"545_CR159","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","volume":"35","author":"HC Kuo","year":"2016","unstructured":"Kuo, H. C., Jiang, Y. H., Tsai, Y. C. & Kuo, Y. C. Intravesical botulinum toxin\u2010A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2013a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol. Urodyn. 35, 609\u2013614 (2016).","journal-title":"Neurourol. Urodyn."},{"key":"545_CR160","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.juro.2017.10.018","volume":"199","author":"RA Pinto","year":"2018","unstructured":"Pinto, R. A. et al. Intratrigonal onabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome\/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J. Urol. 199, 998\u20131003 (2018).","journal-title":"J. Urol."},{"key":"545_CR161","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrurol.2014.204","volume":"11","author":"HH Lai","year":"2014","unstructured":"Lai, H. H. Clinical trials: placebo effects in interstitial cystitis\/bladder pain syndrome. Nat. Rev. Urol. 11, 494 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"545_CR162","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1464-410X.2009.08427.x","volume":"104","author":"KS Coyne","year":"2009","unstructured":"Coyne, K. S. et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 104, 352\u2013360 (2009).","journal-title":"BJU Int."},{"key":"545_CR163","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/archinte.166.21.2381","volume":"166","author":"V Kupelian","year":"2006","unstructured":"Kupelian, V. et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch. Intern. Med. 166, 2381\u20132387 (2006).","journal-title":"Arch. Intern. Med."},{"key":"545_CR164","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-010-0605-8","volume":"29","author":"SA Martin","year":"2011","unstructured":"Martin, S. A., Haren, M. T., Marshall, V. R., Lange, K. & Wittert, G. A. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J. Urol. 29, 179\u2013184 (2011).","journal-title":"World J. Urol."},{"key":"545_CR165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams, P. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61, 37\u201349 (2003).","journal-title":"Urology"},{"key":"545_CR166","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke, C. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 67, 1099\u20131109 (2015).","journal-title":"Eur. Urol."},{"key":"545_CR167","unstructured":"Brasure, M. et al. Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review (Agency for Healthcare Research and Quality 2016)."},{"key":"545_CR168","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13438","volume":"73","author":"J Meng","year":"2019","unstructured":"Meng, J. et al. Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: evidence from 5285 patients. Int. J. Clin. Pract. 73, e13438 (2019).","journal-title":"Int. J. Clin. Pract."},{"key":"545_CR169","volume":"9","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH) in China: results from the China Health and Retirement Longitudinal Study. BMJ Open 9, e022792 (2019).","journal-title":"BMJ Open"},{"key":"545_CR170","first-page":"1","volume":"22","author":"C Vuichoud","year":"2015","unstructured":"Vuichoud, C. & Loughlin, K. R. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can. J. Urol. 22, 1\u20136 (2015).","journal-title":"Can. J. Urol."},{"key":"545_CR171","doi-asserted-by":"crossref","DOI":"10.1007\/s11934-015-0544-4","volume":"16","author":"I Sorokin","year":"2015","unstructured":"Sorokin, I., Schatz, A. & Welliver, C. Placebo medication and sham surgery responses in benign prostatic hyperplasia treatments: implications for clinical trials. Curr. Urol. Rep. 16, 73 (2015).","journal-title":"Curr. Urol. Rep."},{"key":"545_CR172","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","volume":"154","author":"MJ Barry","year":"1995","unstructured":"Barry, M. J. et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J. Urol. 154, 1770\u20131774 (1995).","journal-title":"J. Urol."},{"key":"545_CR173","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell, J. D. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387\u20132398 (2003).","journal-title":"N. Engl. J. Med."},{"key":"545_CR174","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","volume":"61","author":"RS Kirby","year":"2003","unstructured":"Kirby, R. S. et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61, 119\u2013126 (2003).","journal-title":"Urology"},{"key":"545_CR175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","volume":"335","author":"H Lepor","year":"1996","unstructured":"Lepor, H. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. 335, 533\u2013540 (1996).","journal-title":"N. Engl. J. Med."},{"key":"545_CR176","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0149-2918(95)80073-5","volume":"17","author":"CA Byrnes","year":"1995","unstructured":"Byrnes, C. A. et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study. Clin. Ther. 17, 956\u2013969 (1995).","journal-title":"Clin. Ther."},{"key":"545_CR177","first-page":"1251","volume":"155","author":"JC Nickel","year":"1996","unstructured":"Nickel, J. C. et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 155, 1251 (1996).","journal-title":"CMAJ"},{"key":"545_CR178","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1464-410x.1998.00554.x","volume":"81","author":"J Nickel","year":"1998","unstructured":"Nickel, J. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br. J. Urol. 81, 383\u2013387 (1998).","journal-title":"Br. J. Urol."},{"key":"545_CR179","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn, C. G. et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the LIFT Study. J. Urol. 190, 2161\u20132167 (2013).","journal-title":"J. Urol."},{"key":"545_CR180","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.urology.2013.05.005","volume":"82","author":"H Porst","year":"2013","unstructured":"Porst, H. et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 82, 667\u2013673 (2013).","journal-title":"Urology"},{"key":"545_CR181","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11255-012-0317-7","volume":"45","author":"RP Regadas","year":"2013","unstructured":"Regadas, R. P. et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int. Urol. Nephrol. 45, 39\u201343 (2013).","journal-title":"Int. Urol. Nephrol."},{"key":"545_CR182","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.urology.2017.05.011","volume":"106","author":"K Eredics","year":"2017","unstructured":"Eredics, K., Madersbacher, S. & Schauer, I. A relevant midterm (12 months) placebo effect on lower urinary tract symptoms and maximum flow rate in male lower urinary tract symptom and benign prostatic hyperplasia \u2014 a meta-analysis. Urology 106, 160\u2013166 (2017).","journal-title":"Urology"},{"key":"545_CR183","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000052398","volume":"38","author":"P Zimmern","year":"2000","unstructured":"Zimmern, P. Medical treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials? Eur. Urol. 38, 18\u201324 (2000).","journal-title":"Eur. Urol."},{"key":"545_CR184","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fnins.2019.00160","volume":"13","author":"P Enck","year":"2019","unstructured":"Enck, P. & Klosterhalfen, S. Does sex\/gender play a role in placebo and nocebo effects? Conflicting evidence from clinical trials and experimental studies. Front. Neurosci. 13, 160 (2019).","journal-title":"Front. Neurosci."},{"key":"545_CR185","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2147\/JPR.S134745","volume":"10","author":"SM Vambheim","year":"2017","unstructured":"Vambheim, S. M. & Flaten, M. A. A systematic review of sex differences in the placebo and the nocebo effect. J. Pain. Res. 10, 1831 (2017).","journal-title":"J. Pain. Res."},{"key":"545_CR186","first-page":"104","volume":"14","author":"G Liccardi","year":"2004","unstructured":"Liccardi, G. et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J. Investig. Allergol. Clin. Immunol. 14, 104\u2013107 (2004).","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"545_CR187","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.biopsych.2015.07.019","volume":"79","author":"L Colloca","year":"2016","unstructured":"Colloca, L., Pine, D. S., Ernst, M., Miller, F. G. & Grillon, C. Vasopressin boosts placebo analgesic effects in women: a randomized trial. Biol. Psychiatry 79, 794\u2013802 (2016).","journal-title":"Biol. Psychiatry"},{"key":"545_CR188","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.0963-7214.2005.00384.x","volume":"14","author":"S Siegel","year":"2005","unstructured":"Siegel, S. Drug tolerance, drug addiction, and drug anticipation. Curr. Direct Psychol. Sci. 14, 296\u2013300 (2005).","journal-title":"Curr. Direct Psychol. Sci."},{"key":"545_CR189","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000365248","volume":"61","author":"K Weimer","year":"2015","unstructured":"Weimer, K., Colloca, L. & Enck, P. Age and sex as moderators of the placebo response \u2014 an evaluation of systematic reviews and meta-analyses across medicine. Gerontology 61, 97\u2013108 (2015).","journal-title":"Gerontology"},{"key":"545_CR190","doi-asserted-by":"crossref","unstructured":"Cumming, G. Understanding the New Statistics: Effect Sizes, Confidence Intervals, and Meta-Analysis (Routledge, 2013).","DOI":"10.4324\/9780203807002"},{"key":"545_CR191","first-page":"1","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru, C. What\u2019s in a name: \u2018significant\u2019 results? JBI Evid. Synth. 13, 1\u20133 (2015).","journal-title":"JBI Evid. Synth."},{"key":"545_CR192","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-015-0658-6","volume":"17","author":"SK Rai","year":"2015","unstructured":"Rai, S. K., Yazdany, J., Fortin, P. R. & Avi\u00f1a-Zubieta, J. A. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res. Ther. 17, 143 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"545_CR193","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","volume":"7","author":"AG Copay","year":"2007","unstructured":"Copay, A. G., Subach, B. R., Glassman, S. D., Polly, D. W. Jr & Schuler, T. C. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 7, 541\u2013546 (2007).","journal-title":"Spine J."},{"key":"545_CR194","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich, K. W., Tierney, W. M. & Wolinsky, F. D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J. Clin. Epidemiol. 52, 861\u2013873 (1999).","journal-title":"J. Clin. Epidemiol."},{"key":"545_CR195","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0005-7894(84)80002-7","volume":"15","author":"NS Jacobson","year":"1984","unstructured":"Jacobson, N. S., Follette, W. C. & Revenstorf, D. Psychotherapy outcome research: methods for reporting variability and evaluating clinical significance. Behav. Ther. 15, 336\u2013352 (1984).","journal-title":"Behav. Ther."},{"key":"545_CR196","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0005-7894(86)80061-2","volume":"17","author":"NS Jacobson","year":"1986","unstructured":"Jacobson, N. S., Follette, W. C. & Revenstorf, D. Toward a standard definition of clinically significant change. Behav. Ther. 17, 308\u2013311 (1986).","journal-title":"Behav. Ther."},{"key":"545_CR197","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/135581969900400410","volume":"4","author":"N Black","year":"1999","unstructured":"Black, N. et al. Consensus development methods: a review of best practice in creating clinical guidelines. J. Health Serv. Res. Policy 4, 236\u2013248 (1999).","journal-title":"J. Health Serv. Res. Policy"},{"key":"545_CR198","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2648.1994.tb01207.x","volume":"19","author":"HP McKenna","year":"1994","unstructured":"McKenna, H. P. The Delphi technique: a worthwhile research approach for nursing? J. Adv. Nurs. 19, 1221\u20131225 (1994).","journal-title":"J. Adv. Nurs."},{"key":"545_CR199","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.urology.2019.08.004","volume":"133","author":"R Lim","year":"2019","unstructured":"Lim, R., Liong, M. L., Lim, K. K., Leong, W. S. & Yuen, K. H. The minimum clinically important difference of the International Consultation on Incontinence Questionnaires (ICIQ-UI SF and ICIQ-LUTSqol). Urology 133, 91\u201395 (2019).","journal-title":"Urology"},{"key":"545_CR200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.urology.2018.01.024","volume":"115","author":"TW Fuller","year":"2018","unstructured":"Fuller, T. W., Ristau, B. T., Tepe, S. M. & Benoit, R. M. Characterizing clinically meaningful changes in lower urinary tract symptoms using the American Urological Association symptom index. Urology 115, 139\u2013143 (2018).","journal-title":"Urology"},{"key":"545_CR201","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","volume":"287","author":"AJ Barsky","year":"2002","unstructured":"Barsky, A. J., Saintfort, R., Rogers, M. P. & Borus, J. F. Nonspecific medication side effects and the nocebo phenomenon. JAMA 287, 622\u2013627 (2002).","journal-title":"JAMA"},{"key":"545_CR202","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/00006842-200207000-00007","volume":"64","author":"KJ Petrie","year":"2002","unstructured":"Petrie, K. J., Cameron, L. D., Ellis, C. J., Buick, D. & Weinman, J. Changing illness perceptions after myocardial infarction: an early intervention randomized controlled trial. Psychosom. Med. 64, 580\u2013586 (2002).","journal-title":"Psychosom. Med."},{"key":"545_CR203","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","volume":"336","author":"TJ Kaptchuk","year":"2008","unstructured":"Kaptchuk, T. J. et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336, 999\u20131003 (2008).","journal-title":"BMJ"},{"key":"545_CR204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.39093.464190.55","volume":"334","author":"KJ Petrie","year":"2007","unstructured":"Petrie, K. J. et al. Effect of providing information about normal test results on patients\u2019 reassurance: randomised controlled trial. BMJ 334, 352 (2007).","journal-title":"BMJ"},{"key":"545_CR205","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1037\/0033-295X.89.5.507","volume":"89","author":"R Eikelboom","year":"1982","unstructured":"Eikelboom, R. & Stewart, J. Conditioning of drug-induced physiological responses. Psychol. Rev. 89, 507 (1982).","journal-title":"Psychol. Rev."},{"key":"545_CR206","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-97-1-112","volume":"97","author":"H Brody","year":"1982","unstructured":"Brody, H. The lie that heals: the ethics of giving placebos. Ann. Intern. Med. 97, 112\u2013118 (1982).","journal-title":"Ann. Intern. Med."},{"key":"545_CR207","volume":"13","author":"M Schaefer","year":"2018","unstructured":"Schaefer, M., Sahin, T. & Berstecher, B. Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS ONE 13, e0192758 (2018).","journal-title":"PLoS ONE"},{"key":"545_CR208","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bioe.12245","volume":"30","author":"C Blease","year":"2016","unstructured":"Blease, C., Colloca, L. & Kaptchuk, T. J. Are open-label placebos ethical? Informed consent and ethical equivocations. Bioethics 30, 407\u2013414 (2016).","journal-title":"Bioethics"},{"key":"545_CR209","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jebm.12251","volume":"10","author":"JE Charlesworth","year":"2017","unstructured":"Charlesworth, J. E. et al. Effects of placebos without deception compared with no treatment: a systematic review and meta\u2010analysis. J. Evid. Based Med. 10, 97\u2013107 (2017).","journal-title":"J. Evid. Based Med."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00545-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T20:19:47Z","timestamp":1699993187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":209,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1038\/s41585-021-00545-2","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"18 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F.S. is an advisory board member and\/or speaker for Astellas, AstraZeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Jansen, Lissy, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi and Wolff. C.G.R. is a consultant for GSK, Lilly, Procept, NxThera, Neotract and Sophiris and has previously received grants or research support from NxThera, Neotract, Procept and Astellas. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}